The FDA is warning consumers about the dangers of tianeptine, a drug being sold at gas stations, convenience stores, vape ...

Atzumi combines a proprietary advanced powder and device technology to simplify nasal delivery of dihydroergotamine for acute treatment of migraine.

Previously called STS101, the company said Wednesday that the drug’s brand name is Atzumi and is indicated for acute migraine ...

The Trump administration has proposed cutting a $56 million grant that teaches first responders how to use the lifesaving ...

The US Food and Drug Administration (FDA) has approved Atzumi, a 5.2 mg dihydroergotamine (DHE) nasal powder, for the acute ...

Approval is based on results from the Phase III ASCEND trial, in which patients using the powder achieved freedom from pain ...

Courtesy Lowenthal For decades, people suffering life-threatening allergic reactions had to quickly and correctly give ...

For five years, the clinical-stage pharmaceutical company has developed Enbumyst, a nasal spray intended to remove excess ...